HRP20140586T1 - Peptidi za lijeäśenje beta-amiloidoze - Google Patents

Peptidi za lijeäśenje beta-amiloidoze Download PDF

Info

Publication number
HRP20140586T1
HRP20140586T1 HRP20140586AT HRP20140586T HRP20140586T1 HR P20140586 T1 HRP20140586 T1 HR P20140586T1 HR P20140586A T HRP20140586A T HR P20140586AT HR P20140586 T HRP20140586 T HR P20140586T HR P20140586 T1 HRP20140586 T1 HR P20140586T1
Authority
HR
Croatia
Prior art keywords
compound
amino acid
acid sequence
peptide
use according
Prior art date
Application number
HRP20140586AT
Other languages
English (en)
Inventor
Markus Mandler
Christian Gieffers
Frank Mattner
Andrea Dolischka
Oleksandr Otava
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of HRP20140586T1 publication Critical patent/HRP20140586T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (17)

1. Uporaba barem jednog spoja koji sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: SEFKHG(C), TLHEFRH(C), ILFRHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), SPNQFRH(C), ELFKHHL(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C) i TEFRHKA(C), naznačena time, da je za proizvodnju lijeka za sprečavanje i/ili liječenje B-amiloidoze.
2. Uporaba barem jednog spoja koji sadrži sljedeću aminokiselinsku sekvencu: X1RX2DX3(X4)n(X4)m(X6)o (formula I), naznačena time, da X1 je izoleukin (I) ili valin (V), X2 je triptofan (W) ili tirozin (Y), X3 je treonin (T), valin (V), alanin (A), metionin (M), glutamin (Q) ili glicin (G), X4 je prolin (P), alanin (A), tirozin (Y), serin (S), cistein (C) ili glicin (G), X5 je prolin (P), leukin (L), glicin (G) ili cistein (C), X6 je cistein (C), a n, m i o su, međusobno neovisno, 0 ili 1, dok spomenuti spoj ima kapacitet vezivanja na protutijelo koje je specifično za epitop od amiloid-beta-peptida (Aβ), koji sadrži aminokiselinsku sekvencu EFRHDSGY i/ili pEFRHDSGY, pri čemu je ta uporaba za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
3. Uporaba prema zahtjevu 2, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) i IRWDGG(C).
4. Uporaba barem jednog spoja koji sadrži sljedeću aminokiselinsku sekvencu EX1WHX2X3(X4)n(X5)m (formula II), naznačena time, da X1 je valin (V), arginin (R) ili leukin (L), X2 je arginin (R) ili glutaminska kiselina (E), X3 je alanin (A), histidin (H), lizin (K), leukin (L), tirozin (Y) ili glicin (G), X4 je prolin (P), histidin (H), fenilalanin (F) ili glutamin (Q) ili cistein, X5 je cistein (C), i n i m su međusobno neovisno 0 ili 1, dok spomenuti spoj ima kapacitet vezivanja na protutijelo koje je specifično za epitop od amiloid-beta-peptida (Aβ), koji sadrži aminokiselinsku sekvencu EVHHQKL, pri čemu je ta uporaba za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
5. Uporaba prema zahtjevu 4, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRC(C), EVWHRH(C) i ERWHEK(C), poželjno EVWHRHQ(C), WRWHEKH(C), EVWHRLQ(C), ELWHRYP(C) i ELWHRAF(C).
6. Uporaba barem jednog spoja koji sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine: QDFRHY(C), SEFKHG (C), TSFRHG (C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL(C), TLHEFRH(C), ATFRHSP(C), APMYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL (C), ATPLFRH (C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSVC(C), ADHDFRH(C), DGLLFKH(C), MFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C) HEFRH i HEFRH (C), naznačena time, da je za proizvodnju lijeka za sprečavanje i/ili liječenje β-amiloidoze.
7. Uporaba prema zahtjevu 6, naznačena time, da spoj sadrži peptid koji ima aminokiselinsku sekvencu odabranu iz skupine koju čine: QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHC(C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), SPNQFRH(C), TLHEFRH(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), DGLLFKH(C), EELRHSV(C), TEFRHKA(C), (C)SEFKH, SEFKH(C), (C)HEFRH i HEFRH(C), poželjno SEFKHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), ILFRHG(C), SPNQFRH(C), ELFKHHL(C), TLHEFRH(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C), TEFRHKA(C).
8. Uporaba prema bilo kojem od zahtjeva 1 do 7, naznačena time, da navedeni spoj je polipeptid koji sadrži 4 do 20 aminokiselinskih ostataka.
9. Uporaba prema bilo kojem od zahtjeva 1 do 8, naznačena time, da spoj je vezan na farmaceutski prihvatljiv nosač, poželjno KLH (Keyhole Limpet Hemocyanin).
10. Uporaba prema bilo kojem od zahtjeva 1 do 9, naznačena time, da spoj je formuliran za intravenoznu, subkutanu, intradermalnu ili intramuskularnu primjenu.
11. Uporaba prema bilo kojem od zahtjeva 1 do 10, naznačena time, da spoj je formuliran s pomoćnim sredstvom, poželjno s aluminijskim hidroksidom.
12. Uporaba prema bilo kojem od zahtjeva 1 do 11, naznačena time, da spoj je u sastavu lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng to 100 μg.
13. Uporaba spoja prema bilo kojem od zahtjeva 1 do 10, naznačena time, da je za liječenje i/ili poboljšavanje simptoma sinukleinopatije.
14. Uporaba prema zahtjevu 13, naznačena time, da sinukleinopatija je odabrana iz sljedeće skupine: Parkinsonova bolest, demencija s Lewyjevim tjelešcima, višestruka atrofija sustava i neurodegeneracija s akumuliranjem željeza u mozgu.
15. Peptid, naznačen time, da ima aminokiselinsku sekvencu odabranu iz skupine koju čine: IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C), IRWDGG(C), EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C), ERWHEK(C), QDFRHY(C), SEFKHG(C), TSFRHG(C), TSVFRH(C), TPFRHT(C), SQFRHY(C), LMFRHN(C), SAFRHH(C), LPFRHG(C), SHFRHG (C), ILFRHG(C), QFKHDL(C), NWFPHP(C), EEFKYS(C), NELRHST(C), GEMRHQP(C), DTYFPRS(C), VELRHSR(C), YSMRHDA(C), AANYFPR(C), SPNQFRH(C), SSSFFPR(C), EDWFFWH(C), SAGSFRH(C), QVMRHHA(C), SEFSHSS(C), QPNLFYH(C), ELFKHHL (C), TLHEFRH(C), ATFRHSP(C), APMYFPH(C), TYFSHSL(C), HEPLFSH(C), SLMRHSS(C), EFLRHTL(C), ATPLFRH(C), QELKRYY(C), THTDFRH(C), LHIPFRH(C), NELFKHF(C), SQYFPRP(C), DEHPFRH(C), MLPFRHG(C), SAMRHSL(C), TPLMFWH(C), LQFKHST(C), ATFRHST(C), TGLMFKH(C), AEFSHWH(C), QSEFKHW(C), AEFMHSV(C), ADHDFRH(C), DGLLFKH(C), IGFRHDS(C), SNSEFRR(C), SELRHST(C), THMEFRR(C), EELRHSV(C), QLFKHSP(C), YEFRHAQ(C), SNFRHSV(C), APIQFRH(C), AYFPHTS(C), NSSELRH(C), TEFRHKA(C), TSTEMWH(C), SQSYFKH(C), (C)SEFKH, SEFKH(C), (C)HEFRH i HEFRH(C).
16. Peptid prema zahtjevu 15, naznačen time, da je taj peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
17. Farmaceutska formulacija, poželjno cjepivo, naznačeno time, da sadrži peptid prema zahtjevu 15 ili 16.
HRP20140586AT 2008-06-12 2009-06-12 Peptidi za lijeäśenje beta-amiloidoze HRP20140586T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0095108A AT506819B1 (de) 2008-06-12 2008-06-12 Vakzin zur behandlung von alzheimer-krankheit
PCT/AT2009/000236 WO2009149486A2 (en) 2008-06-12 2009-06-12 Compounds for treating diseases

Publications (1)

Publication Number Publication Date
HRP20140586T1 true HRP20140586T1 (hr) 2014-09-12

Family

ID=41401982

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140586AT HRP20140586T1 (hr) 2008-06-12 2009-06-12 Peptidi za lijeäśenje beta-amiloidoze

Country Status (21)

Country Link
US (2) US8613931B2 (hr)
EP (1) EP2310034B9 (hr)
JP (2) JP2011522841A (hr)
KR (1) KR20110036808A (hr)
CN (1) CN102123727B (hr)
AT (3) AT506819B1 (hr)
AU (1) AU2009257169B2 (hr)
BR (1) BRPI0915137A2 (hr)
CA (1) CA2723991A1 (hr)
CY (1) CY1115316T1 (hr)
DK (1) DK2310034T3 (hr)
ES (1) ES2461492T3 (hr)
HR (1) HRP20140586T1 (hr)
IL (1) IL209895A (hr)
MX (1) MX2010013648A (hr)
PL (1) PL2310034T3 (hr)
PT (1) PT2310034E (hr)
RS (1) RS53236B (hr)
RU (1) RU2553345C2 (hr)
SI (1) SI2310034T1 (hr)
WO (1) WO2009149486A2 (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012172427A2 (en) * 2011-06-14 2012-12-20 National Taiwan University Peptide compounds for inhibition of platelet aggregation
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP2659908A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
DK3137094T3 (da) 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR102964291B1 (ko) * 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
MX2019000047A (es) * 2016-06-29 2019-07-04 Univ California Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
JP7761373B2 (ja) * 2017-05-30 2025-10-28 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア Ｔｄｐ－４３のｒｎａ認識モチーフ１（ｒｒｍ１）中のエピトープ、およびそれらに対するミスフォールディング選択的抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN109985231A (zh) * 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
CN115698060A (zh) * 2020-03-10 2023-02-03 生命爱科 环肽
AU2021276401A1 (en) 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
CN116472055A (zh) 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
CN116724046A (zh) * 2020-09-17 2023-09-08 欧萨尔普罗席纳有限公司 用于治疗阿尔茨海默病之β淀粉样蛋白疫苗
CN112608926A (zh) * 2020-12-08 2021-04-06 安徽大千生物工程有限公司 一种用于检测β淀粉样蛋白的基因序列组、杂交瘤细胞组及胶乳增强免疫比浊法试剂盒
CN113061161B (zh) * 2021-04-02 2023-09-12 河南省农业科学院动物免疫学重点实验室 靶向amyloid-beta结构的抑制性肽配基及应用
IL312360A (en) * 2021-10-28 2024-06-01 Abbvie Inc Anti-amyloid beta antibodies and methods of using them
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
RU2294211C2 (ru) * 2001-01-19 2007-02-27 Цитос Байотекнолоджи Аг Композиция и способ для иммунизации, способ продуцирования неприродного, упорядоченного и повторяющегося массива антигенов
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
US20050176030A1 (en) 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
WO2007106536A2 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2008002893A2 (en) 2006-06-29 2008-01-03 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
WO2009091518A2 (en) * 2008-01-15 2009-07-23 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits

Also Published As

Publication number Publication date
KR20110036808A (ko) 2011-04-11
ES2461492T3 (es) 2014-05-20
IL209895A0 (en) 2011-02-28
EP2310034A2 (en) 2011-04-20
CY1115316T1 (el) 2017-01-04
DK2310034T3 (da) 2014-04-28
EP2310034B9 (en) 2014-12-17
PL2310034T3 (pl) 2014-08-29
RU2553345C2 (ru) 2015-06-10
US20110097351A1 (en) 2011-04-28
WO2009149486A2 (en) 2009-12-17
EP2310034B1 (en) 2014-03-26
AU2009257169A1 (en) 2009-12-17
AT509106B1 (de) 2011-12-15
PT2310034E (pt) 2014-06-05
JP2015147771A (ja) 2015-08-20
HK1152470A1 (en) 2012-03-02
SI2310034T1 (sl) 2014-05-30
US20130230545A1 (en) 2013-09-05
CN102123727B (zh) 2015-06-10
AT509106A1 (de) 2011-06-15
JP6041917B2 (ja) 2016-12-14
AT509105A1 (de) 2011-06-15
MX2010013648A (es) 2011-04-05
AT509105B1 (de) 2011-12-15
AT506819B1 (de) 2011-06-15
CA2723991A1 (en) 2009-12-17
BRPI0915137A2 (pt) 2016-02-16
JP2011522841A (ja) 2011-08-04
AU2009257169B2 (en) 2015-06-25
WO2009149486A3 (en) 2010-06-10
US8613931B2 (en) 2013-12-24
RU2011100126A (ru) 2012-07-20
IL209895A (en) 2015-09-24
CN102123727A (zh) 2011-07-13
AT506819A1 (de) 2009-12-15
RS53236B (sr) 2014-08-29

Similar Documents

Publication Publication Date Title
HRP20160594T1 (hr) Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima
RU2011100125A (ru) Соединения для лечения амилоидозов
RU2011100126A (ru) Применение мимотопов для лечения бетта-амилоидозов
HRP20151148T1 (hr) Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja
HRP20240906T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
RU2016120641A (ru) Новые полипептиды
JP2013518115A5 (hr)
PE20231841A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
WO2009034134A3 (en) Use of natriuretic peptides for treating angioedema syndromes
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
WO2012012600A3 (en) Peptide compounds for regulating the complement system
WO2015157508A1 (en) Peptidomimetic macrocycles with pth activity
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
JP2006514104A5 (hr)
RU2017105866A (ru) Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения
HRP20141215T1 (hr) Analozi oksintomodulina
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
JP2010536714A5 (hr)
HRP20191965T1 (hr) Stabilizirani polipeptidi faktora rasta slični inzulinu
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2007535910A5 (hr)
JP2009533355A5 (hr)
Ryu et al. Discodermins FH, cytotoxic and antimicrobial tetradecapeptides from the marine sponge Discodermia kiiensis: Structure revision of discodermins AD
JP2018505153A5 (hr)
WO2015138784A3 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis